Sara Karlovitch | Authors

Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.


Acalabrutinib Plus Venetoclax and Rituximab Signals Safety, Efficacy in MCL

January 11, 2022

In an interview with Targeted Oncology, Michael Wang, MD, a professor in the department of lymphoma and myeloma at MD Anderson Cancer Center, discussed the safety, efficacy, and tolerability of acalabrutinib plus venetoclax and rituximab in mantle cell lymphoma.